My colleague Shingai Machingaidze in South Africa & I wrote about this in @bmj.com

Gilead’s global access plan leaves BIG gaps

It’s especially shocking that they banned Argentina, Brazil, Mexico & Peru from buying generic versions—nations where Gilead tested its drug

https://www.bmj.com/content/bmj/387/bmj.q2254.full.pdf